DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS
PLOS One · 2025
DOI: 10.1371/journal.pone.0338091 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Shuang Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The People's Hospital of Liaoning Province, People's Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: DNA Methylation, Liver Neoplasms, Carcinoma, Hepatocellular, Glutaminase. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Key Research and Development Projects of Liaoning Province.
Abstract (Originalsprache)
Background
Aberrant DNA methylation plays a pivotal role in cancer progression by enhancing oncogene activation or silencing tumor suppressor genes, contributing to malignant phenotypes. Methylation driver genes (MDGs) are characterized by an inverse correlation between DNA methylation levels and mRNA expression, making them critical targets for cancer research.
Methods
We analyzed the liver hepatocellular carcinoma (LIHC) dataset from The Cancer Genome Atlas (TCGA) using the R package MethylMix to identify MDGs. Prognostic models were developed through univariate Cox regression, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox regression to identify core genes. We further evaluated the associations of these genes with the tumor immune microenvironment, immune checkpoint inhibitors (ICIs), and chemotherapeutic sensitivity. Finally, liver cancer tissue organoid culture experiments combined with DNA methylation sequencing were conducted to validate predictions of drug sensitivity.
Results
A total of 21 MDGs were identified, among which GNA14, glutaminase (GLS), and GNG4 were selected to construct a prognostic risk score model. The model demonstrated robust predictive performance, with Receiver Operating Characteristic (ROC) values of 0.723, 0.764, and 0.716 for 1-, 3-, and 5-year survival, respectively. Among these, GLS emerged as a key gene, showing low methylation levels and high mRNA expression, which were associated with poor prognosis, significant alterations in the tumor immune microenvironment, and differential sensitivity to ICIs and chemotherapeutic agents.
Conclusion
The three-gene MDG-based prognostic model effectively predicts survival outcomes in LIHC patients. Moreover, the methylation status of GLS serves as a biomarker for assessing immune microenvironment characteristics, responsiveness to immunotherapy, and chemotherapy sensitivity, highlighting its potential as a therapeutic target in liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The People's Hospital of Liaoning Province, People's Hospital of China Medical University, Shenyang, Liaoning, China.
- School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
- Department of Hepatobiliary Surgery, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China.
ORCID-Profile: Lijie He
Förderung
- The Key Research and Development Projects of Liaoning Province
Zitieren
APA
Zheng, S., Yu, X., Wang, X., Ma, Y., Han, Y., Zhang, J., Wu, W., Sun, C., & He, L. (2025). DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS. PLOS One. https://doi.org/10.1371/journal.pone.0338091
Vancouver
Zheng S, Yu X, Wang X, Ma Y, Han Y, Zhang J, et al. DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS. PLOS One. 2025. doi:10.1371/journal.pone.0338091
BibTeX
@article{Zheng2025,
author = {Zheng, Shuang and Yu, Xi and Wang, Xiaozhou and Ma, Yi and Han, Yujia and Zhang, Jing and Wu, Wei and Sun, Chunyu and He, Lijie},
title = {DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0338091}
}
EUVIMED